Natto: Release of NattoPharma 's results for Q2 2015 Wednesday 26. August 2015 at 08:30 hours.

The same day, the company will hold a presentation of the quarterly results at the conference center of KS - Agenda , Haakon VII's gate 9, Oslo 26. August 2015 at 08.30 hours.

The presentation will be held by CEO Hogne Vik. Breakfast will be served.

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the purest vitamin K2 on the market. MenaQ7 is the only vitamin K2 with proven positive clinical health effects on bones and the cardiovascular system. MenaQ7 vitamin K2 is the only vitamin K2 supported by several granted patents on cardiovascular health worldwide.

About NattoPharma

As a biotechnology and nutraceutical company, NattoPharma is the worldwide pioneer and innovator for developing, documenting and provide Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear positive clinical efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in a research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik

CEO, NattoPharma

Mobil: +47 97 53 53 26

E-mail: hogne.vik@nattopharma.com

Tags: